SCYX Profile
SCYNEXIS, Inc. is a biotechnology company focused on the development of innovative treatments for fungal infections. Based in Jersey City, New Jersey, SCYNEXIS is at the forefront of addressing complex fungal diseases with its lead product candidate, Ibrexafungerp. This novel oral and intravenous drug is designed to treat a range of serious fungal infections, including recurrent vulvovaginal candidiasis (VVC), invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company's flagship treatment, BREXAFEMME (ibrexafungerp tablets), is already approved for the treatment of VVC and represents a significant advancement in managing this common and often challenging condition.
Ibrexafungerp is poised to make a substantial impact in the antifungal market with its broad-spectrum activity and innovative mechanism of action. The drug has completed the Phase 3 CANDLE study, which focused on its efficacy in preventing recurrent VVC, underscoring its potential for addressing both acute and chronic fungal infections. This research highlights SCYNEXIS's commitment to advancing the treatment options available to patients suffering from severe fungal infections.
The company has established strategic research collaborations with major pharmaceutical and healthcare firms, including Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC. These partnerships are crucial for the development and commercialization of Ibrexafungerp, helping to expand its reach and application across various markets. These collaborations reflect SCYNEXIS's robust approach to leveraging external expertise and resources to enhance its drug development and distribution capabilities.
Incorporated in 1999, SCYNEXIS, Inc. was initially known as SCYNEXIS Chemistry & Automation, Inc. before adopting its current name in June 2002. The company's evolution and focus on pioneering antifungal therapies underscore its dedication to improving patient outcomes in the realm of infectious disease. SCYNEXIS continues to push the boundaries of fungal infection treatment, aiming to deliver new solutions that address unmet medical needs and offer hope for more effective management of these challenging conditions.
|
